# Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

> **NCT02526160** · PHASE3 · COMPLETED · sponsor: **Kyowa Kirin, Inc.** · enrollment: 134 (actual)

## Conditions studied

- X-linked Hypophosphatemia

## Interventions

- **BIOLOGICAL:** burosumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02526160
- **Lead sponsor:** Kyowa Kirin, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-22
- **Primary completion:** 2016-12-22
- **Final completion:** 2018-12-06
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2024-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02526160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02526160, "Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02526160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*